Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)

Scopus

Scopus profile and journal metrics

This journal is indexed in Scopus. Use these metrics for a quick publishing snapshot, then open the Scopus page for the authoritative profile.

Scopus
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Indexed in Scopus since 2022
CiteScore 1.0
Indexed since 2022
First decision 7 Days
Submission to acceptance 45 Days
Acceptance to publication 14 Days
Acceptance rate 8%

SCImago

SCImago Journal Rank preview

Use SCImago when you want a quick visual view of the journal ranking profile and external discoverability signals.

Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) SCImago Journal & Country Rank

DOAJ

Directory of Open Access Journals listing

The DOAJ record is useful for readers, librarians, and authors who want a direct open-access directory entry for the journal.

DOAJ
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Open directory record
In Press Original full research article

Prevalence of Prediabetes among University Staff and the Clinical Utility of the American Diabetes Association Risk Test as A Screening Tool: A Cross-Sectional Study 2022

Published
2025-08-26
Full text

Keywords

  • Palestine.
  • Prediabetes
  • University Staff
  • ADA risk test

Abstract

Prediabetes, a precursor to type 2 diabetes mellitus (T2DM), warrants urgent attention given its global prevalence and heightened burden in Palestine. This cross-sectional study assessed prediabetes prevalence, associated risk factors, and the validity of the American Diabetes Association (ADA) Prediabetes Risk Test among An-Najah National University (ANNU) staff. A 10-month investigation enrolled 365 adults (>18 years), collecting sociodemographic data via interviewer-administered questionnaires. Prediabetes was defined per WHO criteria (HbA1c 5.7%–6.49%), with blood glucose measured via HbA1c testing. The ADA risk test (English version) was employed, and statistical analyses (IBM SPSS v21.0) included sensitivity, specificity, predictive values, and ROC-AUC calculations. Among participants (60.8% male), prediabetes prevalence was 10.1%, with 8 undiagnosed T2DM cases identified. Multivariate regression identified age ≥50 years (50–59: OR=3.1, p=0.02; ≥60: OR=4.6, p=0.01) and obesity (BMI ≥30: OR=2.8, p=0.03) as significant predictors. The ADA test demonstrated moderate accuracy at a ≥4 cut off (sensitivity=72%, specificity=69%, AUC=0.738). This study highlights a concerning prevalence of prediabetes (10.1%) among ANNU staff, with age and obesity as critical modifiable risk factors in Palestine. The ADA tool’s moderate predictive efficacy supports its use for non-invasive screening in resource-limited settings. These findings highlight the need for targeted public health strategies to enhance prediabetes awareness, promote early lifestyle interventions, and mitigate T2DM progression. Further regional studies are recommended to validate these associations and refine risk assessment protocols.

Article history

Received
2025-03-25
Accepted
2025-05-22
Available online
2025-08-26
قيد النشر بحث أصيل كامل

Prevalence of Prediabetes among University Staff and the Clinical Utility of the American Diabetes Association Risk Test as A Screening Tool: A Cross-Sectional Study 2022

Published
2025-08-26
البحث كاملا

الكلمات الإفتتاحية

  • Palestine.
  • Prediabetes
  • University Staff
  • ADA risk test

الملخص

Prediabetes, a precursor to type 2 diabetes mellitus (T2DM), warrants urgent attention given its global prevalence and heightened burden in Palestine. This cross-sectional study assessed prediabetes prevalence, associated risk factors, and the validity of the American Diabetes Association (ADA) Prediabetes Risk Test among An-Najah National University (ANNU) staff. A 10-month investigation enrolled 365 adults (>18 years), collecting sociodemographic data via interviewer-administered questionnaires. Prediabetes was defined per WHO criteria (HbA1c 5.7%–6.49%), with blood glucose measured via HbA1c testing. The ADA risk test (English version) was employed, and statistical analyses (IBM SPSS v21.0) included sensitivity, specificity, predictive values, and ROC-AUC calculations. Among participants (60.8% male), prediabetes prevalence was 10.1%, with 8 undiagnosed T2DM cases identified. Multivariate regression identified age ≥50 years (50–59: OR=3.1, p=0.02; ≥60: OR=4.6, p=0.01) and obesity (BMI ≥30: OR=2.8, p=0.03) as significant predictors. The ADA test demonstrated moderate accuracy at a ≥4 cut off (sensitivity=72%, specificity=69%, AUC=0.738). This study highlights a concerning prevalence of prediabetes (10.1%) among ANNU staff, with age and obesity as critical modifiable risk factors in Palestine. The ADA tool’s moderate predictive efficacy supports its use for non-invasive screening in resource-limited settings. These findings highlight the need for targeted public health strategies to enhance prediabetes awareness, promote early lifestyle interventions, and mitigate T2DM progression. Further regional studies are recommended to validate these associations and refine risk assessment protocols.

Article history

تاريخ التسليم
2025-03-25
تاريخ القبول
2025-05-22
Available online
2025-08-26